Company: ANTX
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0000950170-25-052852
Chunk: 16

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 16
---
 University Foundation, Indiana University - Simon Comprehensive Cancer Center, P2K Dynamics, Inc. and Regenstrief Institute. Ms. Martin received a B.S. in Accounting from the Kelley School of Business at Indiana University and an M.B.A. from Harvard Business School. We believe that Ms. Martin’s 25 years of experience as an executive at biopharmaceutical companies makes her an appropriate member of our Board.

Rob Readnour, Ph.D.,has served as a member of our Board since November 2019. Since July 2018, Dr. Readnour hasserved as the Managing Director at Mountain Group Partners, a venture capital firm that invests in early-stage companies in the science, agricultural technology, and technology sectors. From October 1990 to June 2018, Dr. Readnour served in multiple senior management positions at Elanco Animal Health Incorporated, a publicly traded pharmaceutical company that was previously part of Eli Lilly & Co., including Senior Director of Product Development and Senior Advisor and Chief Scientific Officer at Elanco Alternative Innovation. Dr. Readnour currently serves as a member of the board of or has visitation rights to several private companies, including Advanced Animal Diagnostics, a diagnostics company developing point-of-care tests across various human and animal applications, Targan, a bio-systems company focused on animal health, Vytelle and Verility, animal health fertility companies, Velo-1, an animal health drug development company building a portfolio of high-value prescription medicines for companion animals, Skyline Vet Pharma, a veterinary pharmaceutical company, and Exubrion Therapeutics, a radiotherapeutic veterinary device company. Dr. Readnour also currently serves as the Chairman of In the Bowl Animal Health, Inc., an animal health company, and serves as Executive Chairman of Borah, an animal health discovery company. Dr. Readnour received a Ph.D. in Analytical Chemistry from University of Illinois and a B.S. in Chemistry from Southeast Missouri State University. We believe that Dr. Readnour’s more than 30 years of experience moving products from discovery through commercialization makes him an appropriate member of our Board.

Melvin Spigelman, M.D.,has served as a member of our Board since February 2022. Since January 2009, Dr.Spigelman has served as President and Chief Executive Officer for the Global Alliance for TB Drug Development, a non-profit organization which seeks to accelerate the discovery and development of faster-acting and affordable drugs to fight tuberculosis. From June